Application of a modified clinical classification for pulmonary arterial hypertension associated with congenital heart disease in children: emphasis on atrial septal defects and transposition of the great arteries. An analysis from the TOPP registry.

"Conflict of interest The M3C-Necker contracts with Actelion, Bayer, Novartis, MSD and Lilly for DB to perform consultant activities and to participate in steering committees for clinical trials. MB has received grants from and contracted as consultant for Actelion and Bayer-Schering; and served as a consultant and participated in the steering committee for Actelion/Janssen, Acceleron, AOP, Bayer-Schering, GlaxoSmithKline, and Eli Lilly, The University of Colorado contracts with Acceleron, Actelion/Janssen, Altavant, Bayer, Gilead, Gossamer Bio, Lilly, MSD and United Therapeutics for DI to be a consultant. The University Medical Center Groningen contracts with Actelion, GlaxoSmithKline, MSD, and Lilly for RB to perform consultant activities and to participate in steering committees for clinical trials. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare that financial support was received for the research, authorship, and/or publication of this article.The TOPP (Tracking-Outcomes-and-Practice-in-Pediatric-Pulmonary-Hypertension) registry is supported by an unrestricted research grant from Actelion/Janssen Pharmaceuticals Ltd. Open access funding by University of Geneva. Actelion/Janssen Pharmaceuticals Ltd. was not involved in the study design, analysis, interpretation of data, the writing of this article or the decision to submit it for publication."